Cite
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
MLA
Allison Rosenthal, et al. “Comparisons of Treatment Outcomes of Epcoritamab versus Chemoimmunotherapy, Polatuzumab-Based Regimens, Tafasitamab-Based Regimens, or Chimeric Antigen Receptor T-Cell Therapy, in Third-Line or Later Relapsed/Refractory Large B-Cell Lymphoma.” Journal of Hematology & Oncology, vol. 17, no. 1, Aug. 2024, pp. 1–5. EBSCOhost, https://doi.org/10.1186/s13045-024-01594-x.
APA
Allison Rosenthal, Javier Munoz, Monika Jun, Tongsheng Wang, Alex Mutebi, Anthony Wang, Shibing Yang, Kojo Osei-Bonsu, Brian Elliott, Fernando Rivas Navarro, Junhua Yu, Samantha Brodkin, Mariana Sacchi, & Andrew Ip. (2024). Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma. Journal of Hematology & Oncology, 17(1), 1–5. https://doi.org/10.1186/s13045-024-01594-x
Chicago
Allison Rosenthal, Javier Munoz, Monika Jun, Tongsheng Wang, Alex Mutebi, Anthony Wang, Shibing Yang, et al. 2024. “Comparisons of Treatment Outcomes of Epcoritamab versus Chemoimmunotherapy, Polatuzumab-Based Regimens, Tafasitamab-Based Regimens, or Chimeric Antigen Receptor T-Cell Therapy, in Third-Line or Later Relapsed/Refractory Large B-Cell Lymphoma.” Journal of Hematology & Oncology 17 (1): 1–5. doi:10.1186/s13045-024-01594-x.